<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Reported-in-House" bill-type="olc" dms-id="HFF657E08DE7F427696F5A766E6935072" key="H" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 2410 RH: Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-05-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">IB</distribution-code>
		<calendar display="yes">Union Calendar No. 258</calendar>
		<congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session>
		<legis-num display="yes">H. R. 2410</legis-num>
		<associated-doc display="yes" role="report">[Report No. 115–354]</associated-doc>
		<current-chamber display="yes">IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action display="yes">
			<action-date date="20170511">May 11, 2017</action-date>
			<action-desc><sponsor name-id="D000096">Mr. Danny K. Davis of Illinois</sponsor> (for himself and <cosponsor name-id="B001248">Mr. Burgess</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<action><action-date>October 19, 2017</action-date><action-desc>Additional sponsor: <cosponsor name-id="B001251">Mr. Butterfield</cosponsor></action-desc></action><action>
			<action-date>October 19, 2017</action-date>
			<action-desc>Committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc>
		</action>
		<action><action-desc><pagebreak></pagebreak></action-desc></action><legis-type>A BILL</legis-type>
		<official-title display="yes">To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and
			 treatment demonstration program and to provide for sickle cell disease
			 research, surveillance, prevention, and treatment.<pagebreak></pagebreak></official-title>
	</form>
	<legis-body id="HF1DE84963B294282A19083D2C9344011" style="OLC">
		<section id="HB5FD428F2192435C95A769A025806E15" section-type="section-one"><enum>1.</enum><header>Short title; table of contents</header>
 <subsection id="H74F29F4ADD4940DC8382C2522A6262EC"><enum>(a)</enum><header>Short title</header><text display-inline="yes-display-inline">This Act may be cited as the <quote><short-title>Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2017</short-title></quote>.</text> </subsection><subsection id="HF6804D9AE08945FFA28D764A64627DAF"><enum>(b)</enum><header>Table of contents</header><text display-inline="yes-display-inline">The table of contents of this Act is as follows:</text>
				<toc container-level="legis-body-container" lowest-bolded-level="division-lowest-bolded" lowest-level="section" quoted-block="no-quoted-block" regeneration="yes-regeneration">
					<toc-entry idref="HB5FD428F2192435C95A769A025806E15" level="section">Sec. 1. Short title; table of contents.</toc-entry>
					<toc-entry idref="H02CF5A4E3647487A91E2164E66C4E179" level="section">Sec. 2. Sickle cell disease research.</toc-entry>
					<toc-entry idref="HF62802C2F9FE4A79A016CAB925A21581" level="section">Sec. 3. Sickle cell disease surveillance.</toc-entry>
					<toc-entry idref="HA7CA1388CE8549B39D4B096717497329" level="section">Sec. 4. Sickle cell disease prevention and treatment.</toc-entry>
					<toc-entry idref="H80F095901C08467F93E8ECDC73B26C06" level="section">Sec. 5. Collaboration with community-based entities.</toc-entry>
				</toc>
 </subsection></section><section id="H02CF5A4E3647487A91E2164E66C4E179"><enum>2.</enum><header>Sickle cell disease research</header><text display-inline="no-display-inline">Part P of title III of the Public Health Service Act is amended by inserting after section 399V–6 (<external-xref legal-doc="usc" parsable-cite="usc/42/280g-17">42 U.S.C. 280g–17</external-xref>) the following:</text>
			<quoted-block display-inline="no-display-inline" id="H4771944AAC5C427DB9E96DD4D5AD87BD" style="OLC">
				<section id="HCA3631F185B44B8C899540DAD1365E3B"><enum>399V–7.</enum><header>National Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Program</header>
 <subsection id="H1171407C189C4BCBB18BBA6B290DEE0F"><enum>(a)</enum><header>Research</header><text>The Secretary may conduct or support research to expand the understanding of the cause of, and to find a cure for, sickle cell disease.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
 </section><section id="HF62802C2F9FE4A79A016CAB925A21581"><enum>3.</enum><header>Sickle cell disease surveillance</header><text display-inline="no-display-inline">Section 399V–7 of the Public Health Service Act, as added by section 2, is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H46A7D192BAF64D139EDE708ADF23FF76" style="OLC">
				<subsection id="H701633849B984C5691394680F805000A"><enum>(b)</enum><header>Surveillance</header>
 <paragraph id="HA95C4B9864CC44B2815649FC153239A6"><enum>(1)</enum><header>Grants</header><text>The Secretary may, for each fiscal year for which appropriations are available to carry out this subsection, make grants to not more than 20 States—</text>
 <subparagraph id="H534622CC31E64C7AA8A5A4BE31277499"><enum>(A)</enum><text>to conduct surveillance and maintain data on the prevalence and distribution of sickle cell disease and its associated health outcomes, complications, and treatments;</text>
 </subparagraph><subparagraph id="HBAF3F2B315224D7EA24AF46C3D5C34AD"><enum>(B)</enum><text display-inline="yes-display-inline">to conduct public health initiatives with respect to sickle cell disease, including—</text> <clause id="HB94CE75BF5384D2EBC0E55EAF5A1C455"><enum>(i)</enum><text display-inline="yes-display-inline">increasing efforts to improve access to, and receipt of, high-quality sickle cell disease-related health care, including the use of treatments approved under section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of this Act;</text>
 </clause><clause id="HCF02C4EC9B994FB0BDF9EF78A82274B4"><enum>(ii)</enum><text>working with partners to improve health outcomes of people with sickle cell disease over the lifespan by promoting guidelines for sickle cell disease screening, prevention, and treatment, including management of sickle cell disease complications;</text>
 </clause><clause id="HD2BE30BAF53049219E152A57C83A5312"><enum>(iii)</enum><text>providing support to community-based organizations and State and local health departments in conducting sickle cell disease education and training activities for patients, communities, and health care providers; and</text>
 </clause><clause id="H9762227E6B5345C8BDBCD9229D2EB89B"><enum>(iv)</enum><text>supporting and training State health departments and regional laboratories in comprehensive testing to identify specific forms of sickle cell disease in people of all ages; and</text>
 </clause></subparagraph><subparagraph id="H13D1313A4CC24CF0A654D0D16634D405"><enum>(C)</enum><text>to identify and evaluate promising strategies for prevention and treatment of sickle cell disease complications, including through—</text>
 <clause id="HDD1881D3CF0C43389D70066E60369A04"><enum>(i)</enum><text>improving estimates of the national incidence and prevalence of sickle cell disease, including estimates about the specific types of sickle cell disease;</text>
 </clause><clause id="H818803E1B9D84EDEA6759785BD3CFF28"><enum>(ii)</enum><text>identifying health disparities related to sickle cell disease;</text> </clause><clause id="H0EA5F417430B4001BDCEB632B0CDF2B7"><enum>(iii)</enum><text>assessing the utilization of therapies and strategies to prevent complications related to sickle cell disease; and</text>
 </clause><clause id="HA68ADB1C2E4D430C879DE1768864C1BF"><enum>(iv)</enum><text>evaluating the impact of genetic, environmental, behavioral, and other risk factors that may affect sickle cell disease health outcomes.</text>
 </clause></subparagraph></paragraph><paragraph id="HE086DCBEA323424A9368CE2E5C0F0EFA"><enum>(2)</enum><header>Population included</header><text>The Secretary shall, to the extent practicable, award grants under this subsection to States across the United States so as to include data on the majority of the United States population with sickle cell disease.</text>
 </paragraph><paragraph id="HABFA487C5FE2473D9F4D60BF84EE7C64"><enum>(3)</enum><header>Application</header><text>To seek a grant under this subsection, a State shall submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may require.</text>
 </paragraph><paragraph id="H5FA3601C2836467D8F4F3C7D451E2E2D"><enum>(4)</enum><header>Definitions</header><text>In this subsection:</text> <subparagraph id="HC75F7D67C7234023B019938BB67F202D"><enum>(A)</enum><text display-inline="yes-display-inline">The term <term>Secretary</term> means the Secretary of Health and Human Services, acting through the Director of the National Center on Birth Defects and Developmental Disabilities.</text>
 </subparagraph><subparagraph id="HAF3AFD0931254AEC8AF3BD49273A3112"><enum>(B)</enum><text>The term <term>State</term> includes the 50 States, the District of Columbia, the Commonwealth of Puerto Rico, the United States Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
		</section><section id="HA7CA1388CE8549B39D4B096717497329"><enum>4.</enum><header>Sickle cell disease prevention and treatment</header>
 <subsection id="HD2A8F03301084597852ABF38E3E644AF"><enum>(a)</enum><header>Reauthorization</header><text display-inline="yes-display-inline">Section 712(c) of the American Jobs Creation Act of 2004 (<external-xref legal-doc="public-law" parsable-cite="pl/108/357">Public Law 108–357</external-xref>; <external-xref legal-doc="usc" parsable-cite="usc/42/300b-1">42 U.S.C. 300b–1</external-xref> note) is amended—</text>
 <paragraph id="H819376E2F2394548AAF7E4EC35755BF9"><enum>(1)</enum><text>by striking <quote>Sickle Cell Disease</quote> each place it appears and inserting <quote>sickle cell disease</quote>;</text> </paragraph><paragraph id="H78D36BFDBBA845C9AD96AC4532E9C4AD"><enum>(2)</enum><text display-inline="yes-display-inline">in paragraph (1)(A), by striking <quote>grants to up to 40 eligible entities for each fiscal year in which the program is conducted under this section for the purpose of developing and establishing systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease</quote> and inserting <quote>grants to up to 25 eligible entities for each fiscal year in which the program is conducted under this section for the purpose of developing and establishing systemic mechanisms to improve the prevention and treatment of sickle cell disease in populations with a high density of sickle cell disease patients</quote>;</text>
 </paragraph><paragraph id="HFBA7B62484B9436E973ECC152C721E42"><enum>(3)</enum><text>in paragraph (1)(B)—</text> <subparagraph id="H2F6F4BE5C0E54DC9B76A58ED0A2F1FE4"><enum>(A)</enum><text>by striking clause (ii) (relating to priority); and</text>
 </subparagraph><subparagraph id="HC98EBE335E1248DD93E4DD7FC3A01097"><enum>(B)</enum><text>by striking <quote><header-in-text level="subparagraph" style="OLC">Grant award requirements</header-in-text></quote> and all that follows through <quote>The Administrator shall</quote> and inserting <quote><header-in-text level="subparagraph" style="OLC">Geographic diversity</header-in-text>.—The Administrator shall</quote>;</text> </subparagraph></paragraph><paragraph id="H8D69EF90507B41939F3BEBE8E1573060"><enum>(4)</enum><text>in paragraph (2), by adding the following new subparagraph at the end:</text>
					<quoted-block display-inline="no-display-inline" id="HAFD0789EDB8140BAABBAA6FD2E396B06" style="OLC">
 <subparagraph id="H47EB0517D01B4E5D8B1124EB0EF41A0A"><enum>(E)</enum><text>To expand, coordinate, and implement transition services for adolescents with sickle cell disease making the transition to adult health care.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HD08DE8F83283443CBDB1B735D2A56053"><enum>(5)</enum><text display-inline="yes-display-inline">in paragraph (6), by striking <quote>$10,000,000 for each of fiscal years 2005 through 2009</quote> and inserting <quote>$4,455,000 for each of fiscal years 2018 through 2022</quote>.</text> </paragraph></subsection><subsection id="HDF634BE7CE72497A9814679A59D68B05"><enum>(b)</enum><header>Technical changes</header><text>Subsection (c) of section 712 of the American Jobs Creation Act of 2004 (<external-xref legal-doc="public-law" parsable-cite="pl/108/357">Public Law 108–357</external-xref>; <external-xref legal-doc="usc" parsable-cite="usc/42/300b-1">42 U.S.C. 300b–1</external-xref> note), as amended by subsection (a), is—</text>
 <paragraph id="HE584DDC08203473E9209C748B9436885"><enum>(1)</enum><text>transferred to the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/201">42 U.S.C. 201</external-xref> et seq.); and</text> </paragraph><paragraph id="HB9D06156A4704B23B127958E0EB1BFF3"><enum>(2)</enum><text>inserted at the end of section 399V–7 of such Act, as added and amended by sections 2 and 3 of this Act.</text>
 </paragraph></subsection></section><section id="H80F095901C08467F93E8ECDC73B26C06"><enum>5.</enum><header>Collaboration with community-based entities</header><text display-inline="no-display-inline">Section 399V–7 of the Public Health Service Act, as amended by section 4, is further amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H43C232B539B845DA8C85402F2B5AAA62" style="OLC">
 <subsection id="H6E2F92C10B4F47B691AE762A88EE34BF"><enum>(d)</enum><header>Collaboration with community-Based entities</header><text display-inline="yes-display-inline">To be eligible to receive a grant or other assistance under subsection (b) or (c), an entity must have in effect a collaborative agreement with a community-based organization with 5 or more years of experience in providing services to sickle cell disease patients.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
	<endorsement display="yes">
		<action-date>October 19, 2017</action-date>
		<action-desc>Committed to the Committee of the Whole House on the State of the Union and ordered to be printed</action-desc></endorsement>
</bill>


